## Sebastian Klammt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1366286/publications.pdf

Version: 2024-02-01

35 papers

2,833 citations

411340 20 h-index 30 g-index

36 all docs 36 docs citations

times ranked

36

1981 citing authors

#	Article	IF	CITATIONS
1	Comparison of changes in albumin binding capacity during hemodiafiltration or hemodialysis with middle cut off membranes. International Journal of Artificial Organs, 2021, 44, 297-301.	0.7	1
2	Occurrence of Gastrointestinal Parasites in Small Mammals from Germany. Vector-Borne and Zoonotic Diseases, 2020, 20, 125-133.	0.6	4
3	MEDI0382, a GLPâ€1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a singleâ€dose, healthyâ€subject, randomized, Phase 1 study. British Journal of Clinical Pharmacology, 2018, 84, 2325-2335.	1.1	54
4	Artificial Liver Treatment: When and Which One?., 2017,, 505-522.		O
5	Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure – a prospective, randomised crossover study. Critical Care, 2016, 20, 2.	2.5	63
6	MP637REDUCED ALBUMIN FUNCTION IS ASSOCIATED WITH INCREASED MORTALITY IN END STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i552-i553.	0.4	0
7	Reducing the underreporting of percutaneous exposure incidents: A single-center experience. American Journal of Infection Control, 2016, 44, 941-943.	1.1	15
8	Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Open Forum Infectious Diseases, 2016, 3, ofw011.	0.4	54
9	Artificial Liver Treatment, When and Which One?. , 2016, , 1-18.		O
10	Artificial Liver Treatment, When and Which One?. , 2016, , 1-18.		0
11	No Sustained Impact of Intermittent Extracorporeal Liver Support on Thrombocyte Time Course in a Randomized Controlled Albumin Dialysis Trial. Therapeutic Apheresis and Dialysis, 2014, 18, 502-508.	0.4	2
12	Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin. BMC Immunology, 2013, 14, 10.	0.9	19
13	<i><i><scp>P</scp>neumocystis jirovecii</i> colonization among renal transplant recipients. Nephrology, 2013, 18, 382-387.</i>	0.7	22
14	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology, 2013, 57, 1153-1162.	3.6	452
15	Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial. Respiratory Research, 2013, 14, 114.	1.4	7
16	Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Surface Antigen Seasonal Influenza Vaccine Produced in Mammalian Cell Culture and Administered to Young and Elderly Adults with and without A(H1N1) Pre-Vaccination. PLoS ONE, 2013, 8, e70866.	1.1	12
17	Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins. Nephrology Dialysis Transplantation, 2012, 27, 2377-2383.	0.4	62
18	Industrial stabilizers caprylate and $\langle i \rangle N \langle  i \rangle$ -acetyltryptophanate reduce the efficacy of albumin in liver patients. Liver Transplantation, 2011, 17, 705-709.	1.3	15

#	Article	IF	Citations
19	Albumin Dialysis MARS: Knowledge from 10 Years of Clinical Investigation. ASAIO Journal, 2009, 55, 498-502.	0.9	46
20	No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. European Journal of Clinical Pharmacology, 2009, 65, 81-87.	0.8	55
21	Increase of Octanoate Concentrations During Extracorporeal Albumin Dialysis Treatments. Therapeutic Apheresis and Dialysis, 2009, 13, 437-443.	0.4	10
22	Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis. Liver Transplantation, 2008, 14, 1333-1339.	1.3	54
23	Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 257-263.	0.8	60
24	Albumin Regeneration in Liver Support-Comparison of Different Methods. Therapeutic Apheresis and Dialysis, 2006, 10, 108-117.	0.4	56
25	The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. European Journal of Clinical Pharmacology, 2006, 62, 29-36.	0.8	108
26	Albumin dialysis with the Molecular Adsorbents Recirculating System (MARS) for liver support – Impact on pharmacokinetics of strongly and less albumin bound drugs. BMC News and Views, 2004, 4, .	0.0	0
27	Extracorporeal support of the failing liver. Current Opinion in Critical Care, 2002, 8, 171-177.	1.6	22
28	Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology, 2002, 36, 949-958.	3.6	2
29	Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology, 2002, 36, 949-958.	3.6	368
30	Albumin dialysis using the molecular adsorbent recirculating system. Current Opinion in Nephrology and Hypertension, 2001, 10, 777-783.	1.0	46
31	Improvement of Multiple Organ Functions in Hepatorenal Syndrome During Albumin Dialysis with the Molecular Adsorbent Recirculating System. Therapeutic Apheresis and Dialysis, 2001, 5, 417-422.	0.4	109
32	Extracorporeal Detoxification Using the Molecular Adsorbent Recirculating System for Critically Ill Patients with Liver Failure. Journal of the American Society of Nephrology: JASN, 2001, 12, S75-S82.	3.0	214
33	Liver Support by Extracorporeal Blood Purification: A Clinical Observation. Liver Transplantation, 2000, 6, 603-613.	1.3	127
34	Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial. Liver Transplantation, 2000, 6, 277-286.	1.3	543
35	Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial. Liver Transplantation, 2000, 6, 277-286.	1.3	227